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HIV-1 Rev escorts unspliced viral mRNAs out of the nucleus of infected cells, which allows formation of infectious HIV-1 virions. We
have identified a putative DEAD box (Asp–Glu–Ala–Asp) RNA helicase, DDX1, as a cellular co-factor of Rev, through yeast and
mammalian two-hybrid systems using the N-terminal motif of Rev as bbaitQ. DDX1 is not a functional homolog of HIV-1 Rev, but down-
regulation of DDX1 resulted in an alternative splicing pattern of Rev-responsive element (RRE)-containing mRNA, and attenuation of Gag
p24 antigen production from HLfb rev() cells rescued by exogenous Rev. Co-transfection of a DDX1 expression vector with HIV-1
significantly increased viral production. DDX1 binding to Rev, as well as to the RRE, strongly suggest that DDX1 affects Rev function
through the Rev–RRE axis. Moreover, down-regulation of DDX1 altered the steady state subcellular distribution of Rev, from nuclear/
nucleolar to cytoplasmic dominance. These findings indicate that DDX1 is a critical cellular co-factor for Rev function, which maintains the
proper subcellular distribution of this lentiviral regulatory protein. Therefore, alterations in DDX1–Rev interactions could induce HIV-1
persistence and targeting DDX1 may lead to rationally designed and novel anti-HIV-1 strategies and therapeutics.
D 2004 Elsevier Inc. All rights reserved.
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Rev is one of the early gene products expressed during
the human immunodeficiency virus type I (HIV-1) repli-
cation cycle. After viral entry into host cells, Rev is
expressed from fully spliced viral mRNA, as also observed
for the viral regulatory proteins, Tat and Nef (Hope and
Pomerantz, 1995; Kjems and Askjaer, 2000; Pollard and
Malim, 1998). Wild-type Rev expression is required for0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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antz, 1995; Feinberg et al., 1986). Hence, expression of Rev
below a threshold level may be responsible for some
mechanisms of cellular persistence or latency of HIV-1
infection (Pomerantz et al., 1992). Wild-type Rev enables
the unspliced and single-spliced viral mRNAs to be
exported to the cytoplasm, where viral structural proteins
can be translated and genomic viral RNA may be
encapsidated. The efficient nuclear/cytoplasmic RNA traf-
ficking is accomplished by a cognate association between
Rev and the Rev-responsive element (RRE) within the
target lentiviral RNA, on the basis of multiple interactions
with cellular co-factors.
To date, two major Rev domains, a nuclear/nucleolar
localization signal (NLS) and a nuclear export signal (NES),
have been investigated and several co-factors were identi-04) 471–480
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tin) for the NES and h-importin for the NLS (Pollard and
Malim, 1998). In addition, the N-terminus has also been
found to be crucial for Rev function, as certain deletions ormutations in the region resulted in diminished or absent Rev
activity (Daly et al., 1995; Hope et al., 1990; Kubota and
Pomerantz, 1998, 2000; Malim et al., 1989; Van Ryk and
Venkatesan, 1999). Such mutants are characterized by: (1)
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intron-containing viral transcripts from the nucleus; (3) loss
of dominant nuclear/nucleolar localization; (4) inefficient
multimerization of Rev; and (5) a dominant-negative
phenotype (Fang et al., 2002). A small domain with 15
amino acid residues in the N-terminus of HIV-1 Rev was
identified by our group as a nuclear diffusion inhibitory
signal (NIS; Kubota and Pomerantz, 1998, 2000), which is
required to maintain the nuclear dominant subcellular
distribution and function of Rev. We hypothesized that such
effects of NIS in Rev would likely be accomplished by the
association between the Rev NIS and specific cellular co-
factor(s). We now report on the identification of a novel
DEAD box protein, as a counterpart of the Rev NIS, which
is demonstrated to be a critical cellular co-factor supporting
HIV-1 replication.Results
Association of HIV-1 Rev with DDX1, a putative RNA
helicase
By using NIS (Rev 10–24: EDLLKAVRLIKFLYQ) as
bbaitQ, we identified five clones showing interactions with
NIS, through yeast two-hybrid screening of a cDNA
library from the human Jurkat CD4+ T-cell-line. Nucleo-
tide sequence determination and analysis revealed that
two of the five positive clones were identical, and
represented partial cDNAs from the human DDX1 gene
(NM-004939), encoding 145 aa of this full-length, 740 aa
nuclear-localized DEAD box protein (Godbout and
Squire, 1993). DEAD box proteins contain seven
conserved domains and are considered to be putative
RNA helicases (Fig. 1A; Godbout and Squire, 1993;
Godbout et al., 1998).
The association of Rev and a fragment of the DDX1
gene product (189 H to 333L; NISYP-1 for NIS yeast
positive clone 1) was then confirmed in a mammalian
two-hybrid system (Fig. 1B). The 15-residue NIS of HIV-
1 Rev demonstrated a strongly positive signal with the
DDX1 fragment, indicating the association of NIS and
DDX1. Interestingly, wild-type Rev (as a Gal–Rev fusion
protein) yielded an approximately three-fold stronger
signal than that of NIS alone, indicating stable inter-Fig. 1. Association between DDX1 and HIV-1 Rev. (A) The full-length DDX1 m
DDX1 segment interacting with the NIS signal of HIV-1 Rev. (B) In vivo interac
plasmid DNA was transfected into Cos-1 cells in six-well plates. The reporter plas
(PC: positive control), (2) pcDNA3.0 (NC: negative control), (3) pSG5GAL-Revd
vector), (4) pSG5GAL-Rev + pSG5NISYP-1-VP, or (5) pSG5Gal-NIS + pSG5NIS
with error bars) from triplicate samples. (C) Coomassie blue staining of GST, G
molecular marker lane. (D) GST pull-down assay illustrating in vitro DDX1-R
respectively. Lane 1, 35S-Rev input; lane 2, 35S-Rev + GST; lane 3, 35S-Rev + GST
DDX1 + GST-Rev. (E) Co-immunoprecipitation demonstrates in vivo DDX1-R
Western blot; IP: immunoprecipitation; Ser: Serum.actions of DDX1 with wild-type Rev, which is present in
HIV-1-infected cells. As expected, in contrast to the wild-
type, a NIS-deficient Rev mutant, Revd23 (Fang et al.,
2002), showed no significant signal, indicating loss of
association with DDX1 (Fig. 1B).
We further confirmed the association between full-
length Rev and DDX1 with both in vitro and in vivo
experiments (Figs. 1C, D, and E). In vitro GST pull-
down assays showed significant binding between DDX1
and the GST–Rev fusion protein (Fig. 1D, lane 6), and a
somewhat weaker but clearly demonstrable signal of Rev
binding to the GST–DDX1 fusion protein (Fig. 1D, lane
3). Co-immunoprecipitation assays confirmed that the two
over-expressed proteins bound to each other, revealing an
in vivo physiological interaction in HEK293 cells. Of
note, anti-Rev antibodies used for immunoprecipitation
with anti-DDX1 for Western blotting, as well as the
reciprocal, both demonstrated this intracellular protein–
protein interaction (Fig. 1E).
DDX1 is required for the efficient function of HIV-1 Rev
We next asked whether DDX1 could function analo-
gously to Rev, in facilitating the export of intron-
containing mRNA, also containing the RRE, from the
nucleus. A reporter vector for Rev function, pDM628,
was used in the initial assays. In this system, exoge-
nously expressed Rev protein binds to RRE on the
unspliced reporter mRNA, allowing its export out of the
nucleus for luciferase reporter gene expression. Co-trans-
fection of Cos-1 cells with pDM628 and pcDDX1
yielded a signal only modestly higher than background
(Table 1). Considering the difference that molar quantities
of DNA (DDX1: 2.7 kb, Rev: 0.6 kb) may have on the
signal levels, we repeated the experiments by using
higher quantities of pcDDX1, and observed only approx-
imately a 10% increased signal (data not shown). We
concluded that DDX1 alone is not a potent Rev
functional homolog, but may still alter Rev function.
We then tested, in the same system, the possibility that
DDX1 is required directly for the proper functioning of Rev.
DDX1 has been found ubiquitously expressed in many
human cell-types (Godbout et al., 1998, and our unpublished
observations), where it is available for HIV-1 replication,
with various efficiencies. We utilized, in a complementaryolecule, with schematic illustration of its domains and the position of the
tion of DDX1 and NIS in mammalian cells. In total, 1.0 Ag of normalized
mid, pGBhGal (0.5 Ag), was used in combination with: (1) pSG5GAL-VP
23 + pSG5NISYP-1-VP (189-333; DDX1–VP16 fusion protein expression
YP-1-VP. The results represent mean (columns) and SD (standard deviations
ST-Rev and GST–DDX1 fusion proteins on a 4–20% SDS-PAGE gel. M
ev binding. 35S-Rev and 35S-DDX1 were approximately 17 and 90 kDa
-DDX1; lane 4, 35S-DDX1 input; lane 5, 35S-DDX1 + GST, and lane 6, 35S
ev interaction. For specific procedures, see Materials and methods. WB-
,
-
:
Table 1
Rev-dependant reporter gene expression assay
Plasmid Relative luciferase units (RLU/s) F SD
pDM628 only 439.7 F 57.6
+pcRev 3483.0 F 712.0
+pcDDX1 591.0 F 201.7
Cos-1 cells were transfected with pDM628 (0.1 Ag) + pcDNA3.0 (0.4 Ag),
pDM628 (0.1 Ag) + pcRev (0.4 Ag), and pDM628 (0.1 Ag) + pcDDX1
(0.4 Ag), respectively, in 12-well plates. The cells were lysed 24 h after
infection for luciferase activity assays. The mean and standard deviation
(SD) were from triplicate results for each sample.
J. Fang et al. / Virology 330 (2004) 471–480474fashion, both an antisense RNA to DDX1 (As-DDX1)
approach, as well as RNA interference and designed small
interfering RNAs (siRNA) for down-regulating DDX1
expression levels (siDDX1 used as an abbreviation).Fig. 2. Down-regulation of DDX1 in HEK293 cells. HEK293 cells were transfect
further transfection (A), transfection with phU6P (0.25 Ag) (B), or pAS-DDX1 (0.
rabbit anti-human DDX1 antibody followed by fluorescein isothiocyanate (FITC)
wide-field photomicrographs were obtained with a magnification of 10, utilizi
representative of at least three fields selected randomly. (D) Western blotting anal
antisense DDX1 RNA and siRNA DDX1. (1) pCMV-HA-DDX1 only; (2) pCMVEfficient down-regulation of DDX1 was confirmed by
immunofluorescence analyses (IFA) in pAs-DDX1 trans-
fected HEK293 cells (Fig. 2C), but not in the control cells
(i.e., non-transfected and promoter-only (phu6p-transfected
cells; Figs. 2A and B), and neither the antisense nor siRNA
constructs altered cell viability or proliferation (not illus-
trated). This target sequence was then used for synthesis of
an siDDX1 duplex. Down-regulation by specific siRNA and
antisense moieties to DDX1 was also confirmed by Western
blotting (Fig. 2D). siDDX1, as well as pAs-DDX1, were
transfected into Cos-1 cells. We observed that while
antisense to DDX1 had significant potent inhibitory effects
on Rev function, siDDX1 had an even more robust inhibitory
effect on Rev function, at a concentration of 0.4 AM (Table
2). This may be hypothesized to be secondary to a longered with pcDDX1, under G418 selection for 2 weeks, followed by either no
25 Ag) (C). The cells were treated 48 h later, by fixing and incubation with
-conjugated anti-rabbit antibody. Right panels illustrate DAPI staining. The
ng a Zeiss immunofluorescence microscope. The fields in the figure were
ysis of specific down-regulation of DDX1 expression in HEK293 cells, by
-HA-DDX1 + pAs-DDX1, and (3) pCMV-HA-DDX1 + siRNA DDX1.
Table 2
Inhibitory effects of siDDX1 and antisense DDX1 on Rev function
Plasmid RLU/s F SD
pDM628 only 901.3 F 463.1
+pcRev 3446.1 F 1,239.1
+pcRev + pAs-DDX1 1490.7 F 324.5
+pcRev + siDDX1 61.2 F 12.0
Cos-1 cells were transfected with pDM628 (0.1 Ag), along with pcDNA3.0
(0.4 Ag), pcRev (0.4 Ag), pcRev (0.4 Ag) + siRNA DDX1 (0.04 AM), and
pcRev (0.4 Ag) + pAs-DDX1 (0.2 Ag), respectively, in a 12-well plate. The
cells were lysed 24 h after transfection for luciferase activity assays. The
mean and SD were from triplicate results for each sample.
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to the larger size antisense.
We then confirmed the effects of antisense DDX1 and
siDDX1 in HEK293 cells by achieving similar results as
those described above in Cos-1 cells (data not illustrated),
and further analyzed splicing pattern changes of mRNA
from the RRE-containing reporter plasmid, pDM628, which
reflects the effects on Rev function. Reverse transcriptase-
polymerase chain reactions (RT-PCR) demonstrated a
decreased ratio of unspliced RNA in cytoplasmic versus
nuclear fractions (Fig. 3, first and third row), and an
increased ratio of spliced versus unspliced RNA in the
nuclear fraction (Fig. 3, second and third row), which
supported the hypothesis that both pAs-DDX1 and siDDX1
restricted Rev function. The effects of antisense DDX1 and
siDDX1 may also extend to specific cellular mRNA, as we
observed weakened bands for certain house-keeping
mRNAs (Fig. 3, bottom row).
We extended these studies to analyze HIV-1 replication.
The production of HIV-1 p24 antigen can be restored by
introducing exogenous Rev into a HLfb rev() cell-line,
which contains an integrated, rev-deficient HIV-1 provirus
(Mermer et al., 1990). We used this p24 antigen rescue assay
to investigate the effects of down-regulation of DDX1 onFig. 3. Alteration of splicing patterns of RRE-containing mRNA by
antisense DDX1 and siRNA DDX1. A total quantity of 1.5 Ag DNA was
utilized for transfection of HEK293 cells in each well of a six-well plate,
including: pDM628 (0.2 Ag) alone, pDM628 with pcRev (0.3 Ag), pDM628
with pcRev and pAs-DDX1 (0.6 Ag), and pDM628, pcRev plus siDDX1
(0.3 AM), prior to RT-PCR. M: DNA molecular marker; C: cytoplasmic
fraction; N: nuclear fraction.Rev function. Transfection of siRNA to DDX1 with wild-
type Rev significantly decreased p24 antigen production
(Fig. 4A). These data in toto demonstrated that a lower
DDX1 level limits Rev function, both in Rev-dependant
reporter expression and in Rev-dependant HIV-1 virion
production. Since DDX1 expression is found at various
levels in different cell-types, it is instructive to alsoFig. 4. Effects of DDX1 on HIV-1 replication. Inhibition of HIV-1 p24
antigen rescue by siRNA to DDX1. HLfb rev() cells seeded in 24-well
plates (1  105 cells/well) were transfected with pcRev (0.2 Ag) alone,
pcRev with siRNA to DDX1, or pcRev with siRNA to GFP, at a siRNA
concentration of 0.04 AM. Forty-eight hours post-transfection, the super-
natants were collected for HIV-1 p24 antigen assay. The results are from
triplicate samples. Augmentation of HIV-1 viral production by over-
expressed DDX1. HEK293 cells in 24-well plates were transfected with
pHIV-1-NL4-3 (33.3 ng) and differing quantities of pcDDX1 (30, 150 and
270 ng) per well. Total DNA quantities in each aliquot were standardized to
be 0.33 Ag, supplemented with pcDNA3.0. The supernatants were collected
48 h post-transfection for p24 antigen enzyme-linked immunosorbant
assays (ELISA). The results are mean values with standard deviations (SD)
from triplicate samples.
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expression. The results showed that over-expression of
DDX1 with very low quantities of transfected HIV-1NL4-3,
significantly augmented HIV-1NL4-3 replication (Fig. 4B).
These results demonstrate that cellular DDX1 is required for
proper Rev function, as well as for wild-type HIV-1
replication.
DDX1 is required for proper subcellular localization of
HIV-1 Rev
As nuclear/nucleolar localization of Rev is required
for proper function of this lentiviral regulatory protein,
we analyzed effects of low DDX1 levels on Rev
localization, preliminary to Rev functional assays. The
rationale was that DDX1, as a NIS interacting protein,
should play role(s) in Rev subcellular compartmentaliza-
tion with intact NIS. Just as NIS-deficient Rev (Revd23)
lost its proper localization and function, low cellular
DDX1 levels should also alter localization and function
of Rev, despite NIS integrity. After confirming efficientFig. 5. Aberrant subcellular distribution of Rev in DDX-1-down-regulated Cos-1 c
DDX1 expression plasmid (B and C) were co-transfected with pcRev (1 Ag). The
antibody, at a dilution of 1:200, followed by detection via a fluorescein isothiocyan
obtained at a magnification of 40. Two typical views of the subcellular distributio
phase-contrast views of the same fields. These cells were analyzed via fluorescen
20.down-regulation of DDX1 (see above), co-transfection of
pcRev with pAs-DDX1 in mammalian cells resulted in
clear changes in Rev localization. While pcRev alone
revealed expected nuclear/nucleolar dominance of wild-
type Rev (Fig. 5A), combination of pcRev and pAs-
DDX1 lead to a loss of nuclear/nucleolar dominant
localization (Fig. 5B), and cytoplasmic dominance with
lower quantities of nucleolar localization (Fig. 5C). No
clear differences in Rev levels were detected, secondary
to DDX1 expression. Therefore, we conclude that low
DDX1 expression contributes to disordered Rev sub-
cellular localization, which would likely alter Rev
function and subsequent HIV-1 replication.
Effects of DDX1 on HIV-1 replication occur via the
Rev–RRE axis
Further studies then evaluated whether DDX1 affects
Rev function through Rev-RRE binding, a critical step
generating unspliced HIV-1 genomic RNA delivery from
the nucleus. Specific binding of DDX1 to RRE was assayed,ells. Cos-1 transient transfectants with a parental plasmid (A) or an antisense
cells were fixed 48 h later and incubated in the rabbit anti-Rev polyclonal
ate (FITC)-conjugated anti-rabbit IgG antibody. The photomicrographs were
n of Rev in DDX1-down-regulated cells are illustrated. The right panels are
ce microscopy. The photomicrographs were obtained at a magnification of
Table 3
In vivo RRE binding assay
Plasmids RLU/s F SD
pSLIIBLuc only 303.3 F 79.1
+pTat/DDX1 1394.0 F 105.7
+pTat/DDX1 + pcRev 184.0 F 50.3
+pTat/DDX1 + pcDDX1 840.3 F 304.7
+pTat/Rev 1561.3 F 178.2
+pTat/Rev + pcRev 577.7 F 246.4
+pTat/Rev + pcDDX1 1683.7 F 307.2
Cos-1 cells (1.0  105), in a 12-well plate, were transfected with
pSLIIBLuc (0.1 Ag) and the indicated combination of plasmids. The cells
were lysed 24 h after transfection for luciferase activity assays. The mean
and SD were from triplicate results for each sample.
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luciferase gene expression depends on specific binding
between a Tat–Rev fusion protein and the RRE. In this
experiment, Tat–Rev was replaced by Tat–DDX1, and
luciferase gene expression reflects specific RRE binding.
Studies of Tat–DDX1 and Tat–Rev showed a similar
luciferase activity, indicating that DDX1 is capable of
RRE binding in vivo (Table 3). In this system, addition of
pcRev, for expressing the cognate RRE-binding molecule
and as a competitor of the Tat/DDX1 fusion protein, showed
a significantly inhibited signal, thus indicating specific
binding between DDX1 and the RRE. However, the
magnitude of binding between DDX1 and RRE appears
less robust than between Rev and RRE (Table 3), and DDX1
alone cannot rescue HIV-1 virion production from a Rev-
negative provirus in the absence of Rev (data not
illustrated). The binding of DDX1 to the RRE is, thus,
compared to Rev binding to the RRE, significantly weaker.
These results suggest that DDX1 binding to RRE, as well as
to Rev, may render Rev capable of further interactions in the
HIV-1 life-cycle.Discussion
In this report, we demonstrate the requirement of DDX1
for efficient HIV-1 Rev function, critical roles for DDX1 in
the Rev–RRE axis, and the contribution low-levels of
DDX1 have on altering Rev localization. These data, for
the first time, show the importance of the DEAD box
protein, DDX1, in wild-type HIV-1 Rev function.
The NIS-binding protein, DDX1, clearly alters Rev
function in a divergent manner, as compared to other
important cellular co-factors of Rev that bind to the NLS or
NES (Kjems and Askjaer, 2000). However, DDX1, may
share some characteristics with Sam68, a member of
heteronuclear ribonucleoprotein particle K (hnRNPK)
homology (KH) domain family, as described in certain
although not all articles on this (Li et al., 2002a,b; Lukong
and Richard, 2003; Reddy et al., 1999, 2000). These
include: (1) binding to Rev and the RRE, (2) low-levels
of both factors (Sam68 and DDX1) restrict HIV-1 repli-cation, and (3) over-expression of the factors boost HIV-1
replication. Sam68 enhanced unspliced RNA (including
RRE-containing RNA) export, via pathways including
CRM-1-dependant processes. Nonetheless, data from the
present report and others show that DDX1 is functionally
distinguishable from all descriptions of Sam68, which
suggests potential unique significance for DDX1 (Bleoo et
al., 2001; Chen et al., 2002). Of note, (1) DDX1 is not a Rev
homolog but a factor binding to the unique pathophysio-
logical NIS-motif and suggests that DDX1 affects Rev by
maintaining spatial structure; (2) DDX1 has RNA helicase
and ATPase activities; (3) DDX1 is usually located in both
the nucleoplasm and within cleavage bodies of the nucleus
in which processing of pre-mRNA takes place; and (4)
Binding of DDX1 to the RRE could have a direct action, or
act indirectly mediated by hnRNPK. Importantly, the region
of DDX1 where hnRNPK binds overlaps the Rev-interact-
ing region, which may affect the release of Rev from the
RRE, with ATPase activity, in the cytoplasm.
By combining interpretations of this report and the above
findings and known enzymatic activities of DDX1 (Chen et
al., 2002), we propose a potential model for the effects of
DDX1 on the HIV-1 life-cycle. DDX1, by maintaining
spatial structure of Rev that binds to RRE, may act for an
effective Rev-RRE binding in nucleus; by utilizing its RNA
helicase and ATPase activities, DDX1 may act on altering
RRE spatial structure with consumption of ATP for release
of Rev bound to RRE in the cytoplasm. Regardless of
presence of the RRE, Rev subcellular localization was
altered in DDX1 down-regulated cells from nuclear to
cytoplasmic dominance. We suggest that a decrease in
interaction between NIS and DDX1 molecules may be
responsible for relative sequestering of Rev in the cyto-
plasm, as a result of a dynamic imbalance of Rev trafficking
through the nuclear pore complex (NPC), rather than an
impaired nuclear/nucleolar localization process possibly
mediated by importin-h and the putative Rev cofactor,
B23 (Fankhauser et al., 1991; Kjems and Askjaer, 2000). Of
note, intra-nuclear localization differences between Rev and
DDX1 may inhibit DDX1-induced Rev release from the
RRE, while both are in the nucleus of HIV-1-infected cells.
RNA helicases are known to be involved in virtually
every aspect of RNA metabolism, including transcription,
splicing, ribosome biogenesis, nucleocytoplasmic transport,
translation, and RNA decay (Bleoo et al., 2001; de la Cruz
et al., 1999; Linder and Stutz, 2001; Tanner and Linder,
2001). Nevertheless, the biological functions of DDX1 are
not fully understood. Pathologically, DDX1 is found
amplified in certain neuroblastoma and retinoblastoma
cell-lines (Godbout et al., 1998), and thus it may play
certain roles in the oncogenesis of neural tissues.
Restriction of HIV-1 replication occurs in a variety of
host cells, which could be due to the action of cellular
factors, through either over-expression of inhibitory factors
and/or lack of factors required by HIV-1. For example,
CEM15 or APOBEC-3G is an endogenous inhibitor of HIV-
J. Fang et al. / Virology 330 (2004) 471–4804781 expressed in cell-types in which the absence of HIV-1 Vif
yields a bnon-permissiveQ phenotype for production of
viable virions and can cause hypermutation in newly
synthesized retroviral DNA (Harris et al., 2003; Lecossier
et al., 2003; Mangeat et al., 2003; Sheehy et al., 2002;
Zhang et al., 2003).
Interestingly, the inter-relationship between down-regu-
lated DDX1 and restricted HIV-1 replication is reminiscent
of that found in human astrocytes and certain glial cell-lines.
In those cells, wild-type Rev is not functioning properly due
to a cellular background which induces aberrant subcellular
distribution of Rev [(Neumann et al., 1995, 2001) and our
unpublished studies]. In primary astrocytes as well as a
glioma cell-line, transiently expressed Rev was localized
dominantly in the cytoplasm, which is strikingly similar to
our findings in the DDX1-down-regulated Cos-1 cells. Such
unfavorable microenvironments for Rev contribute to the
inefficiency of HIV-1 replication, as supported by a report
describing Rev inhibition altering intracellular HIV-1 RNA
distribution (Cmarko et al., 2002). Indeed, this similarity
may be a critical clue leading to the elucidation of
mechanisms involved in restricted HIV-1 replication in
human astrocytes and other cell-types.
Finally, if one can reduce the DDX1 expression level to
the least required physiological concentrations in HIV-1
susceptible cells, viral persistence or latency may develop
upon HIV-1 infection due to reduced Rev functions
(Pomerantz et al., 1990). As such, these findings demon-
strate both a new class of cellular cofactors involved in
productive HIV-1 infection and reveal a potential new set of
molecular targets for anti-HIV-1 therapeutics.Materials and methods
Plasmids, siRNAs, and PCR
pcRev expresses wild-type Rev and was reported
previously (Malim et al., 1989). pcDDX1 was derived
from pBluscript SK-DDX1 (Godbout and Squire, 1993), by
inserting the 2.7 kb BamH1–XhoI DDX1 gene into pcDNA
3.0. pSG5Gal-VP, pSG5Gal-Rev and pSG5Gal-Revd23
were described previously (Fang et al., 2002). pSG5Gal-
NIS was constructed by inserting a NIS-encoding oligonu-
cleotide into EcoR1–BamI sites of pSG5Gal-VP. pSG5NI-
SYP-1-VP was constructed by inserting polymerase chain
reaction (PCR)-generated NISYP-1 into EcoR1–HindIII
sites of pSG5Gal-VP. The HIV-1 Rev and DDX1 genes,
generated by PCR, were inserted in pCITE-4 (Novagen,
Madison, WI), a vector for in vitro translation. The Rev and
DDX1 genes were also inserted into the pGEX vector for in
vitro expression and isolation of GST-Rev and GST–DDX1
fusion proteins. The initial plasmids for the in vivo RNA
binding assay, pcTat/Rev, and pSLIIBCAT, were described
previously (Madore et al., 1994). pSLIIBLuc was con-
structed by replacing the chloramphenicol acetyl transferase(CAT) gene between HindIII and BamH1 in pSLIIBCAT
with the luciferase gene. pcTat/DDX1 was constructed by
replacing Rev in pcTat/Rev with XhoI–NcoI full-length
DDX1. pDM128 (Hope et al., 1990), a reporter vector for
Rev function, was modified by replacing the NotI–BamH1
CAT gene in pDM128 with a PCR-generated Not I–Bgl II
luciferase gene. We entitled the resultant vector, pDM628.
The target site for the siRNA DDX1 duplex was:
CAAGCCCTCTTTCCTGCCTG (961–980, X70649; Dhar-
macon, Lafayette, CO). The vector for expressing antisense
RNA to DDX1 (pAs-DDX1) was constructed from
pcDNA3.0, by deleting NruI–SnaBI of the cytomegalovi-
rus (CMV) promoter region and inserting the human U6
promoter (X07425), followed by an oligonucleotide encod-
ing the DDX1 target site, as above, with poly (T). pCMV-
HA-DDX1 was constructed by inserting PCR-generated
DDX1 (SalI–BamH1) into the SalI–BgIII sites of pCMV-
HA (BD Clontech). All constructs were confirmed via
sequence analyses. Three pairs of reverse transcriptase
polymerase chain reaction (RT-PCR) primers, SC05F/
628RTS, SC05F/628RTU and hGAPDH-F/hGAPDH-R
were used for detection of spliced pDM628 (240 bp),
unspliced pDM628 (300 bp) and intron-spanning hGAPDH
(540 bp), respectively. The primer sequences were: SC05F
5VGAAGAAGCGGAGACAGCGACGAAGAGCTC3V,
628RTS 5V CTAACAGCTGCCTTGTAAGTCATTGGTC-
T3V, 628RTU 5VCCAGCGGTTCCATCCTCTAGAGGA-
TAGA3V, hGAPDH-F 5VCCATCACCATCTTCCAGG-
AGCGAGATC3V, hGAPDH-R 5VCAGGTTTTTCTAGQ
CGGCAGGTCAGG3V. Cell fractionation, RNA extrac-
tion techniques, and RT-PCR parameters followed the
manufacturer’s protocol (PARIS and Retroscript Kits,
Ambion, Austin, TX), with minor modifications.
Yeast and mammalian two-hybrid systems
The yeast two-hybrid system was purchased from
Clontech (MATCHMAKER LexA two-hybrid system;
Cat. K1609-1). A cDNA library derived from the Jurkat
T-cell-line (Clontech #HL4513AK) served as the source in
searching for NIS cellular co-factors. The screening process
followed the manufacturer’s instructions with modifications.
A Gal4-VP16-based mammalian two-hybrid system was
employed to examine protein–protein interactions between
DDX1 and Rev molecules in vivo, with modifications of the
reporter construct, using the h-Gal gene instead of the CAT
gene (see Fig. 1 legend; Bogerd and Greene, 1993; Shimano
et al., 1998).
Protein expression and GST pull-down assays
Expression of GST, GST–Rev and GST–DDX1 fusion
proteins, in vitro translation of Rev and DDX1, and GST
pull-down assays were carried out by following protocols,
as described previously (Yang et al., 2001). Briefly, GST,
GST–Rev and GST–DDX1 proteins were expressed in
J. Fang et al. / Virology 330 (2004) 471–480 479competent BL21 cells that were transformed with pGEX,
pGEX–Rev and pGEX–DDX1 vectors, respectively, and
then induced with isopropylthio-h-d-galactoside. The
induced cells were lysed and applied to glutathione-
conjugated agarose bead columns. After intensive washes,
the beads were aliquoted and stored at 20 8C. 35S-labeled
Rev and DDX1 were synthesized utilizing SPT3 kits
(Novagen), following the manufacturer’s protocol. For
GST pull-down assays, GST, GST-DDX1, and GST-Rev-
conjugated bead slurries were mixed with 35S-labeled Rev
or DDX1 in a binding buffer (150 mM NaCl, 20 mM Tris–
HCl (pH 7.5), 0.1% Triton X-100). After binding at 4 8C for
1 h, the mixtures were centrifuged, and the beads were
washed with binding buffer three times. The 35S-Rev and
DDX1 proteins were dissociated from beads by adding
SDS-containing loading buffer, and heating at 95 8C for 5
min. The samples were then electrophoresed on 4–20%
SDS-PAGE gels, and the gels were dried and exposed to X-
ray film.
Cell cultures, transfections, and assays
Cos-1 and HEK293 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) in humidified air containing
5% CO2 at 37 8C. HLfb rev() cells were kindly provided
by the AIDS Reagent Program (N.I.H.; Mermer et al.,
1990). Plasmid and siRNA transfections were carried out
following the manufacturer’s optimized protocols (Fugen6:
Roche). Transfected cells were recovered 48 h post-trans-
fection for reporter and protein expression assays, with the
exception of the 24 h post-transfection samples for
luciferase activity assays (BD PharMingen, San Diego,
CA), using a FB12 luminometer (Berthold Detection
System USA, Oak Ridge, TN). Rev-RRE interactions in
the cells were evaluated by a system to monitor the RRE-
mediated trans-activation of the luciferase gene by the Tat–
Rev protein fusions, as originally described using CAT as a
reporter gene (Madore et al., 1994). Beta-galactosidase (h-
Gal) assays were carried out 48 h after transfection, by
following maker’s protocol (BD Clontech, Palo Alto, CA).
The optical absorbency at a wavelength of 420 nm of each
sample was computed in h-Gal units, according to a
standard curve obtained with sample standards.
Antibodies, immunofluorescence analyses, Western blotting,
and co-immunoprecipitation assays
The rabbit antiserum, Rev 1/20, and rabbit anti-DDX1
antiserum (Godbout et al., 1998) were utilized in the
detection of HIV-1 Rev and cellular DDX1, respectively,
at dilutions of 1:200 in immunofluorescence analyses (IFA).
The fluorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG (Sigma) was employed as a secondary antibody.
Mouse anti-DDX1 monoclonal antibody (BD PharMingen)
and anti-Gal4 murine monoclonal antibody were used in co-immunoprecipitation studies (BD Clontech, Palo Alto, CA).
The co-immunoprecipitation were carried out according the
protocols described previously (Yang et al., 2001). In brief:
HEK293 cells were transfected with pcDDX1 and pcRev or
pGal4Rev. The lysates were treated with rabbit-anti-Rev
(1:1000), rabbit-anti-DDX1 (1:1000) polyclonal antibody,
and normal rabbit serum as a negative control, respectively,
followed by adding protein A beads (Amersham) with
another hour binding reaction, followed by washing with
NETN buffer. The beads were then electrophoresed on a 4–
20% SDS-PAGE gel. Western blotting was utilized to detect
specific DDX1 and Rev proteins, by using monoclonal
mouse-anti-DDX1 antibody and monoclonal mouse-anti-
Gal4 antibody, respectively, as primary antibodies, and
HRP-conjugated anti-mouse as a secondary antibody, the
specific DDX1 and Rev bands were detected, respectively,
utilizing an ECL kit (Amersham).
For Western blotting of DDX1, anti-HA-peroxidase
antibody (Cat. #2013819, Roche) was used to detect HA-
DDX1. Mouse anti-human h-actin was purchased from
ABCam (ab6276, ABcam, Inc., Cambridge, MA).Acknowledgments
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